This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Tuberculosis (TB)	Not applicable	<i>In vitro</i> studies suggest that cationic gold(I) complexes containing 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea could help treat TB. The compounds are gold analogs of platinum cancer therapeutics. <i>In vitro</i> , the gold compounds had selective antimicrobial activity against <i>Mycobacterium tuberculosis</i> without cytotoxicity to mammalian cells. Next steps include testing the compounds <i>in vivo</i> , modifying them for oral bioavailability and determining their molecular target.	Compounds unpatented; licensing status not applicable	Eiter, L. <i>et al.</i> <i>J. Med. Chem.</i> ; published online Oct. 5, 2009; doi:10.1021/jm9012856 Contact: Ulrich Bierbach, Wake Forest University, Winston-Salem, N.C. e-mail: bierbau@wfu.edu
SciBX 2(46); doi:10.1038/scibx.2009.1698				
Published online Dec. 3, 2009				